Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abeona Therapeutics Inc. - Common Stock
(NQ:
ABEO
)
6.345
-1.115 (-14.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4,866,353
Open
6.090
Bid (Size)
6.290 (100)
Ask (Size)
6.470 (300)
Prev. Close
7.460
Today's Range
6.050 - 6.695
52wk Range
4.000 - 7.650
Shares Outstanding
54,191,361
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Abeona Therapeutics Q2 2026 Earnings Call Transcript
↗
Today 11:07 EDT
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For...
Via
Benzinga
Topics
Earnings
Abeona Therapeutics Q2 Earnings Call Highlights
↗
Today 10:05 EDT
Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that...
Via
MarketBeat
Topics
Earnings
Performance
YTD
+19.5%
+19.5%
1 Month
-9.5%
-9.5%
3 Month
+11.1%
+11.1%
6 Month
+25.4%
+25.4%
1 Year
-0.5%
-0.5%
More News
Read More
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
Today 7:30 EDT
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
August 06, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025
↗
March 17, 2026
Via
Chartmill
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
August 04, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
July 21, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona (ABEO) Q1 2026 Earnings Transcript
↗
May 13, 2026
Via
The Motley Fool
Abeona Therapeutics Q1 Earnings Call Highlights
↗
May 13, 2026
Via
MarketBeat
Topics
Earnings
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
↗
May 13, 2026
Via
Benzinga
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
May 13, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
May 11, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Date of First Quarter Financial Results
May 04, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
April 07, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
April 02, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona (ABEO) Q4 2025 Earnings Call Transcript
↗
March 17, 2026
Via
The Motley Fool
Topics
Earnings
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
March 17, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
March 09, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
March 03, 2026
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 6.345
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 08/13/26 04:00 PM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 343.84M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 344M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.